Skip to main content

Table 4 Predictors of mortality following ART initiation

From: A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy

Predictor at ART initiation HR, 95% CI P value Model 1 adjusted HR, 95% CI P value Model 2 Adjusted HR, 95% CI P value
Age (years) 1.04 (0.90 − 1.21) 0.57     
BMI (kg/m2) 0.94 (0.78–1.14) 0.56     
Karnofsky Performance Scale       
  Minor symptoms (90) Reference      
  Moderate symptoms (80) 1.11 (0.11–10.63) 0.93     
  Unable to work (<80) 5.34 (0.55–51.38) 0.15     
  Current tuberculosis 3.01 (0.50–18.02) 0.23     
WHO Stage       
  Stage I Reference      
  Stage II 0.66 (0.04–10.49) 0.77     
  Stage III 0.85 (0.08–9.34) 0.89     
  Stage IV 1.80 (0.11–28.77) 0.68     
CD4 Cell count (cells/μL) 0.99 (0.97–1.01) 0.22     
Log10 Plasma HIV-1 RNA (copies/mL) 3.00 (0.62–14.60) 0.17     
Hemoglobin (g/dL) 0.59 (0.33–1.07) 0.08 0.51 (0.21–1.23) 0.13 0.41 (0.18–0.92) 0.03
Log10 Angiopoietin-1 (ng/mL) 0.25 (0.005–13.63) 0.50     
Log10 Angiopoietin-2 (ng/mL) 18.85 (1.52–233.7) 0.02 41.31 (0.82–2,086) 0.06 75.06 (1.98–2,846) 0.02
Log10 ANG-2/ANG-1 ratio 19.99 (1.66–240.5) 0.02     
Log10 s-ICAM (ng/mL) 10,062 (18.29–5,536,091) 0.004 355.8 (0.22–581,538) 0.12   
Log10 E-selectin (ng/mL) 11.17 (0.18–696.4) 0.25     
Log10 VCAM (ng/mL) 9.33 (0.14–644.0) 0.30     
  1. ART antiretroviral therapy, CI confidence interval, HR hazard ratio.